{"id":"https://openalex.org/W7220658657","doi":"https://doi.org/10.1016/j.ijpx.2026.100679","title":"A n-heneicosane solid emulsion as a single-dose subunit vaccine elicits broad and durable immune responses in an aged and a Pox virus model","display_name":"A n-heneicosane solid emulsion as a single-dose subunit vaccine elicits broad and durable immune responses in an aged and a Pox virus model","publication_year":2026,"publication_date":"2026-10-06","ids":{"openalex":"https://openalex.org/W7220658657","doi":"https://doi.org/10.1016/j.ijpx.2026.100679"},"language":"en","primary_location":{"id":"doi:10.1016/j.ijpx.2026.100679","doi":"https://doi.org/10.1016/j.ijpx.2026.100679","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ijpx.2026.100679","pdf_url":"https://www.sciencedirect.com/science/article/pii/S2590156726001994/pdf","source":{"id":"https://openalex.org/S4210204060","display_name":"International Journal of Pharmaceutics X","issn_l":"2590-1567","issn":["2590-1567"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Pharmaceutics: X","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.sciencedirect.com/science/article/pii/S2590156726001994/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083355007","display_name":"Luis Alberto Ontiveros-Padilla","orcid":"https://orcid.org/0000-0002-7705-9989","observed_orcids":["https://orcid.org/0000-0002-7705-9989"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Luis Ontiveros-Padilla","raw_affiliation_strings":["Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010135405","display_name":"Stephen A. Ehrenzeller","orcid":"https://orcid.org/0000-0002-4078-5362","observed_orcids":["https://orcid.org/0000-0002-4078-5362"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen A. Ehrenzeller","raw_affiliation_strings":["Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5157726226","display_name":"Connor T. Murphy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Connor T. Murphy","raw_affiliation_strings":["Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032308902","display_name":"Denzel D. Middleton","orcid":"https://orcid.org/0000-0001-6446-3870","observed_orcids":["https://orcid.org/0000-0001-6446-3870"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Denzel D. Middleton","raw_affiliation_strings":["Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109678662","display_name":"Grace L. Williamson","orcid":"https://orcid.org/0000-0003-4711-1130","observed_orcids":["https://orcid.org/0000-0003-4711-1130"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Grace L. Williamson","raw_affiliation_strings":["Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5157753760","display_name":"Alexandra M. Lopez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexandra M. Lopez","raw_affiliation_strings":["Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013153851","display_name":"Eric M. Bachelder","orcid":"https://orcid.org/0000-0002-8572-888X","observed_orcids":["https://orcid.org/0000-0002-8572-888X"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric M. Bachelder","raw_affiliation_strings":["Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5079566195","display_name":"Kristy M. Ainslie","orcid":"https://orcid.org/0000-0002-1820-8382","observed_orcids":["https://orcid.org/0000-0002-1820-8382"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I137902535","display_name":"North Carolina State University","ror":"https://ror.org/04tj63d06","country_code":"US","type":"education","lineage":["https://openalex.org/I137902535"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Kristy M. Ainslie","raw_affiliation_strings":["Department of Microbiology & Immunology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA","Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA","Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Microbiology & Immunology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA","institution_ids":["https://openalex.org/I114027177"]},{"raw_affiliation_string":"Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA","institution_ids":["https://openalex.org/I114027177"]},{"raw_affiliation_string":"Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, NC, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I137902535"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5079566195"],"corresponding_institution_ids":["https://openalex.org/I114027177","https://openalex.org/I137902535"],"apc_list":{"value":2590,"currency":"USD","value_usd":2590},"apc_paid":{"value":2590,"currency":"USD","value_usd":2590},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.81316672,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"12","issue":null,"first_page":"100679","last_page":"100679"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11767","display_name":"Poxvirus research and outbreaks","score":0.67330002784729,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11767","display_name":"Poxvirus research and outbreaks","score":0.67330002784729,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.2296999990940094,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10704","display_name":"Advancements in Transdermal Drug Delivery","score":0.028699999675154686,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/single-dose-vaccine","display_name":"single-dose vaccine","score":0.7730000019073486},{"id":"https://openalex.org/keywords/protein-subunit-vaccines","display_name":"subunit vaccine","score":0.972000002861023},{"id":"https://openalex.org/keywords/vaccine-adjuvants","display_name":"vaccine adjuvants","score":0.7680000066757202},{"id":"https://openalex.org/keywords/aged-mice","display_name":"aged mice","score":0.4819999933242798},{"id":"https://openalex.org/keywords/poxvirus","display_name":"poxvirus","score":0.734000027179718},{"id":"https://openalex.org/keywords/immune-response-durability","display_name":"immune response durability","score":0.6389999985694885},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.5960000157356262}],"concepts":[{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.7556999921798706},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.6848000288009644},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5544999837875366},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.5105999708175659},{"id":"https://openalex.org/C104292427","wikidata":"https://www.wikidata.org/wiki/Q899781","display_name":"Protein subunit","level":3,"score":0.4814999997615814},{"id":"https://openalex.org/C2779341262","wikidata":"https://www.wikidata.org/wiki/Q182581","display_name":"Immunity","level":3,"score":0.4377000033855438},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4214000105857849},{"id":"https://openalex.org/C22070199","wikidata":"https://www.wikidata.org/wiki/Q192995","display_name":"Vaccination","level":2,"score":0.3691999912261963},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.3361999988555908},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.335999995470047},{"id":"https://openalex.org/C2780801004","wikidata":"https://www.wikidata.org/wiki/Q1415366","display_name":"Immunization","level":3,"score":0.29980000853538513},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2896000146865845},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.2863999903202057},{"id":"https://openalex.org/C2776387124","wikidata":"https://www.wikidata.org/wiki/Q1475781","display_name":"Virus-like particle","level":4,"score":0.2849000096321106},{"id":"https://openalex.org/C2778117688","wikidata":"https://www.wikidata.org/wiki/Q264024","display_name":"Animal model","level":2,"score":0.27480000257492065},{"id":"https://openalex.org/C3018316044","wikidata":"https://www.wikidata.org/wiki/Q948421","display_name":"Pox virus","level":3,"score":0.2718000113964081},{"id":"https://openalex.org/C3018913218","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody response","level":3,"score":0.25859999656677246}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1016/j.ijpx.2026.100679","doi":"https://doi.org/10.1016/j.ijpx.2026.100679","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ijpx.2026.100679","pdf_url":"https://www.sciencedirect.com/science/article/pii/S2590156726001994/pdf","source":{"id":"https://openalex.org/S4210204060","display_name":"International Journal of Pharmaceutics X","issn_l":"2590-1567","issn":["2590-1567"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Pharmaceutics: X","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:56bbbe4b441042dfb53c5712d06d27b3","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/56bbbe4b441042dfb53c5712d06d27b3","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"International Journal of Pharmaceutics: X, Vol 12, Iss , Pp 100679- (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1016/j.ijpx.2026.100679","doi":"https://doi.org/10.1016/j.ijpx.2026.100679","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ijpx.2026.100679","pdf_url":"https://www.sciencedirect.com/science/article/pii/S2590156726001994/pdf","source":{"id":"https://openalex.org/S4210204060","display_name":"International Journal of Pharmaceutics X","issn_l":"2590-1567","issn":["2590-1567"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Pharmaceutics: X","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9476000070571899,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[{"id":"https://openalex.org/G1638877007","display_name":"NNCI: North Carolina Research Triangle Nanotechnology Network (RTNN)","funder_award_id":"2025064","funder_id":"https://openalex.org/F4320306076","funder_display_name":"National Science Foundation"},{"id":"https://openalex.org/G1676019983","display_name":null,"funder_award_id":"2025064","funder_id":"https://openalex.org/F4320337392","funder_display_name":"Division of Electrical, Communications and Cyber Systems"},{"id":"https://openalex.org/G3275407028","display_name":null,"funder_award_id":"ECCS-2025064","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G584156129","display_name":null,"funder_award_id":"R01 AI167099","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"},{"id":"https://openalex.org/G5973914729","display_name":null,"funder_award_id":"ECCS\u20102025064","funder_id":"https://openalex.org/F4320337392","funder_display_name":"Division of Electrical, Communications and Cyber Systems"},{"id":"https://openalex.org/G9001003695","display_name":null,"funder_award_id":"R01AI167099","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G9001078648","display_name":null,"funder_award_id":"R01AI167099","funder_id":"https://openalex.org/F4320306080","funder_display_name":"Foundation for the National Institutes of Health"}],"funders":[{"id":"https://openalex.org/F4320306076","display_name":"National Science Foundation","ror":"https://ror.org/021nxhr62"},{"id":"https://openalex.org/F4320306080","display_name":"Foundation for the National Institutes of Health","ror":"https://ror.org/00k86s890"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337355","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69"},{"id":"https://openalex.org/F4320337392","display_name":"Division of Electrical, Communications and Cyber Systems","ror":"https://ror.org/01krpsy48"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7220658657.pdf","grobid_xml":"https://content.openalex.org/works/W7220658657.grobid-xml"},"referenced_works_count":48,"referenced_works":["https://openalex.org/W994417814","https://openalex.org/W1051451281","https://openalex.org/W1878522445","https://openalex.org/W1905216348","https://openalex.org/W1988711597","https://openalex.org/W2033852067","https://openalex.org/W2037381306","https://openalex.org/W2045465609","https://openalex.org/W2069542935","https://openalex.org/W2069981713","https://openalex.org/W2079025244","https://openalex.org/W2087032263","https://openalex.org/W2090886777","https://openalex.org/W2105541044","https://openalex.org/W2110223801","https://openalex.org/W2120896592","https://openalex.org/W2134161715","https://openalex.org/W2144887013","https://openalex.org/W2151809081","https://openalex.org/W2345127954","https://openalex.org/W2521741241","https://openalex.org/W2527863850","https://openalex.org/W2605502565","https://openalex.org/W2738277181","https://openalex.org/W2775503072","https://openalex.org/W2964893194","https://openalex.org/W2972334025","https://openalex.org/W2990745657","https://openalex.org/W3082694457","https://openalex.org/W3087285953","https://openalex.org/W3172296615","https://openalex.org/W3209520337","https://openalex.org/W4246504300","https://openalex.org/W4282973584","https://openalex.org/W4304185672","https://openalex.org/W4310642527","https://openalex.org/W4313319367","https://openalex.org/W4318694563","https://openalex.org/W4327950423","https://openalex.org/W4376632012","https://openalex.org/W4389489147","https://openalex.org/W4390055705","https://openalex.org/W4393374725","https://openalex.org/W4394623029","https://openalex.org/W4399274124","https://openalex.org/W4404701630","https://openalex.org/W4410042680","https://openalex.org/W4415269541"],"related_works":[],"abstract_inverted_index":{"The":[0,73,88],"development":[1,38],"of":[2,6,39,170,210,234],"single-dose":[3,229],"vaccines":[4],"capable":[5,233],"inducing":[7,101],"durable":[8,236],"humoral":[9,193],"and":[10,56,65,81,95,116,121,131,146,173,194,244],"cellular":[11,122,148,195],"immune":[12,83,123,216],"responses":[13,120,124,133,176,196],"would":[14],"eliminate":[15],"the":[16,37,70,164,187,208],"need":[17],"for":[18,26,136],"additional":[19],"booster":[20],"doses,":[21],"which":[22],"is":[23],"particularly":[24],"important":[25],"resource-limited":[27],"settings":[28],"or":[29,179],"in":[30,85,125,150,204],"a":[31,40,52,106,140,183,201],"pandemic":[32],"scenario.":[33],"Here,":[34],"we":[35],"report":[36],"sustained-release":[41],"n-heneicosane":[42,112,223],"solid":[43],"emulsion":[44,165],"designed":[45],"to":[46,68,213],"enhance":[47],"subunit":[48,161,241],"vaccine":[49,162,230,242],"immunogenicity":[50],"after":[51,139,154],"single":[53,107,141,202],"administration.":[54],"Fast-":[55],"slow-release":[57,89],"emulsions":[58,74,113,224],"were":[59,75,197],"formulated":[60],"by":[61,77],"varying":[62],"surfactant":[63],"content":[64],"adding":[66],"CpG":[67],"increase":[69],"adjuvant":[71,189],"activity.":[72],"characterized":[76],"release":[78,94],"kinetics,":[79],"cytotoxicity,":[80],"innate":[82],"activation":[84],"dendritic":[86],"cells.":[87],"formulation":[90],"demonstrated":[91],"prolonged":[92],"antigen":[93],"promoted":[96],"pro-inflammatory":[97],"cytokine":[98],"production":[99],"without":[100],"significant":[102],"cytotoxicity.":[103],"In":[104,158],"vivo,":[105],"subcutaneous":[108],"immunization":[109,185,203],"with":[110,186],"antigen-loaded":[111],"elicited":[114],"robust":[115],"long-lasting":[117],"antigen-specific":[118],"antibody":[119,175],"mice.":[126],"A":[127],"Sustained":[128],"IgG,":[129,171],"IgG1":[130,172],"IgG2c":[132],"was":[134,152],"observed":[135,153],"165":[137],"days":[138,156],"immunization,":[142],"while":[143],"an":[144,159,227],"IFN-\u03b3":[145],"IL-2":[147],"response":[149],"splenocytes":[151],"180":[155],"post-immunization.":[157],"Orthopoxvirus":[160],"model,":[163],"platform":[166,212],"induced":[167],"high":[168],"levels":[169,181],"IgG2a":[174],"at":[177],"higher":[178],"comparable":[180],"than":[182],"prime-boost":[184],"MF-59-like":[188],"Addavax.":[190],"Finally,":[191],"strong":[192],"also":[198],"generated":[199],"following":[200],"18-month-old":[205],"mice,":[206],"highlighting":[207],"potential":[209],"this":[211],"overcome":[214],"age-associated":[215],"dysfunction.":[217],"Overall,":[218],"these":[219],"findings":[220],"demonstrate":[221],"that":[222],"function":[225],"as":[226],"effective":[228],"delivery":[231],"system":[232],"promoting":[235],"adaptive":[237],"immunity":[238],"across":[239],"multiple":[240],"models":[243],"aged":[245],"groups.":[246]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2026-10-07T00:00:00"}